Does hybrid capture-based next-generation sequencing (NGS) have special application for detecting actionable genomic alterations in lung adenocarcinoma?

Does hybrid capture-based next-generation sequencing (NGS) have special application for detecting actionable genomic alterations in lung adenocarcinoma?

Does hybrid capture-based next-generation sequencing (NGS) have special application for detecting actionable genomic alterations in lung adenocarcinoma?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Yilong Wu, MD

Yilong Wu, MD

Vice President
Guangdong General Hospital
Guangdong Academy of Medical Sciences
Director, Guangdong Lung Cancer Institute
Guangzhou, China